8-K Announcements
6Material company update
Feb 12, 2026·SEC
Material company update
Feb 5, 2026·SEC
Material company update
Dec 18, 2025·SEC
Zoetis Inc.(ZTS)Earnings, Financials & Key Ratios
ZTS•NYSE
$111.22
$46.95B mkt cap·18.5× P/E·Price updated May 6, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryAnimal health pharmaceuticals and vaccines
AboutZoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.Show more
- Revenue$9.47B+2.3%
- EBITDA$4.08B+5.0%
- Net Income$2.67B+7.5%
- EPS (Diluted)6.02+10.1%
- Gross Margin70.49%+2.0%
- EBITDA Margin43.14%+2.7%
- Operating Margin38%+3.7%
- Net Margin28.23%+5.1%
- ROE65.99%+29.6%
- ROIC26.92%+1.8%
- Debt/Equity2.85+101.6%
- Interest Coverage14.74+5.7%
ZTS Key Insights
Zoetis Inc. (ZTS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 55.6%
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 24.1% free cash flow margin
- ✓13 consecutive years of dividend growth
- ✓Share count reduced 2.4% through buybacks
- ✓Healthy 5Y average net margin of 27.0%
✗Weaknesses
- ✗High debt to equity ratio of 2.8x
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 14.8x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ZTS Price & Volume
Zoetis Inc. (ZTS) stock price & volume — 10-year historical chart
Loading chart...
ZTS Growth Metrics
Zoetis Inc. (ZTS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years7.11%
5 Years7.24%
3 Years5.42%
TTM2.28%
Profit CAGR
10 Years22.94%
5 Years10.29%
3 Years8.13%
TTM7.52%
EPS CAGR
10 Years24.37%
5 Years11.97%
3 Years10.27%
TTM10.05%
Return on Capital
10 Years24.41%
5 Years26.58%
3 Years28.18%
Last Year29.9%
ZTS Recent Earnings
Zoetis Inc. (ZTS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 9/12 qtrs (75%)
Q1 2026Latest
Feb 12, 2026EPS
$1.48
Est $1.40
+5.7%
Revenue
$2.4B
Est $2.4B
+1.1%
Q4 2025
Nov 4, 2025EPS
$1.70
Est $1.62
+4.9%
Revenue
$2.4B
Est $2.4B
-0.4%
Q3 2025
Aug 5, 2025EPS
$1.76
Est $1.62
+8.6%
Revenue
$2.5B
Est $2.4B
+2.1%
Q2 2025
May 6, 2025EPS
$1.48
Est $1.41
+5.0%
Revenue
$2.2B
Est $2.2B
+1.4%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 12, 2026 | $1.48vs $1.40+5.7% | $2.4Bvs $2.4B+1.1% |
| Q4 2025 | Nov 4, 2025 | $1.70vs $1.62+4.9% | $2.4Bvs $2.4B-0.4% |
| Q3 2025 | Aug 5, 2025 | $1.76vs $1.62+8.6% | $2.5Bvs $2.4B+2.1% |
| Q2 2025 | May 6, 2025 | $1.48vs $1.41+5.0% | $2.2Bvs $2.2B+1.4% |
Based on last 12 quarters of dataView full earnings history →
ZTS Peer Comparison
Zoetis Inc. (ZTS) competitors in Animal health pharmaceuticals and vaccines — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ELAN | 13.06B | 26.16 | -55.66 | 6.22% | -4.95% | -3.64% | 0.61 | |
 PCRX | 931.85M | 23.69 | 148.06 | 3.63% | 1.27% | 1.31% | 0.66 | |
 PAHC | 2.38B | 58.64 | 49.28 | 27.37% | 6.29% | 30.81% | 2.67 | |
 IDXX | 46.12B | 579.23 | 44.28 | 10.42% | 24.63% | 70.87% | 0.67 | |
 NEOG | 2B | 9.18 | -1.83 | -3.2% | -68.47% | -28.64% | 0.44 | |
 MRK | 280.48B | 113.56 | 15.60 | 1.18% | 28.12% | 36.14% | 0.96 | |
 PFE | 150.77B | 26.51 | 19.49 | -1.65% | 11.83% | 8.34% | 0.78 | |
 ABBV | 362.56B | 204.98 | 86.49 | 8.57% | 6.91% | 62.15% |
Compare ZTS vs Peers
Zoetis Inc. (ZTS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ZTS Income Statement
Zoetis Inc. (ZTS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 5.31B | 5.83B | 6.26B | 6.67B | 7.78B | 8.08B | 8.54B | 9.26B | 9.47B |
| Revenue Growth % | 8.57% | 9.76% | 7.47% | 6.63% | 16.49% | 3.91% | 5.74% | 8.33% | 2.28% |
| Cost of Goods Sold | 1.86B | 2.03B | 2.15B | 2.22B | 2.46B | 2.6B | 2.71B | 2.86B | 2.79B |
| COGS % of Revenue | 35.12% | 34.82% | 34.3% | 33.21% | 31.69% | 32.23% | 31.72% | 30.9% | 29.51% |
| Gross Profit | 3.44B▲ 0% | 3.8B▲ 10.3% | 4.11B▲ 8.3% | 4.46B▲ 8.4% | 5.31B▲ 19.2% | 5.48B▲ 3.1% | 5.83B▲ 6.5% | 6.4B▲ 9.6% | 6.67B▲ 4.3% |
| Gross Margin % | 64.88% | 65.18% | 65.7% | 66.79% | 68.31% | 67.77% | 68.28% | 69.1% | 70.49% |
| Gross Profit Growth % | 9.54% | 10.28% | 8.32% | 8.39% | 19.16% | 3.09% | 6.54% | 9.63% | 4.33% |
| Operating Expenses | 1.72B | 1.92B | 2.1B | 2.19B | 2.51B | 2.55B | 2.77B | 3B | 3.08B |
| OpEx % of Revenue | 32.33% | 32.89% | 33.47% | 32.79% | 32.27% | 31.53% | 32.36% | 32.45% | 32.49% |
| Selling, General & Admin | 1.32B | 1.48B | 1.64B | 1.73B | 2B | 2.01B | 2.15B | 2.32B | 2.38B |
| SG&A % of Revenue | 24.97% | 25.44% | 26.17% | 25.86% | 25.73% | 24.86% | 25.18% | 25.04% | 25.12% |
| Research & Development | 382M | 432M | 457M | 463M | 508M | 539M | 614M | 686M | 698M |
| R&D % of Revenue | 7.2% | 7.42% | 7.3% | 6.94% | 6.53% | 6.67% | 7.19% | 7.41% | 7.37% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | 1.73B▲ 0% | 1.88B▲ 8.9% | 2.02B▲ 7.3% | 2.27B▲ 12.4% | 2.8B▲ 23.5% | 2.93B▲ 4.5% | 3.07B▲ 4.8% | 3.39B▲ 10.5% | 3.6B▲ 6.0% |
| Operating Margin % | 32.54% | 32.29% | 32.24% | 33.99% | 36.05% | 36.24% | 35.92% | 36.65% | 38% |
| Operating Income Growth % | 23.01% | 8.92% | 7.28% | 12.44% | 23.53% | 4.46% | 4.82% | 10.52% | 6.04% |
| EBITDA | 1.97B | 2.19B | 2.43B | 2.71B | 3.25B | 3.39B | 3.56B | 3.89B | 4.08B |
| EBITDA Margin % | 37.1% | 37.58% | 38.82% | 40.6% | 41.81% | 41.99% | 41.67% | 42.02% | 43.14% |
| EBITDA Growth % | 19.77% | 11.17% | 11.01% | 11.52% | 19.96% | 4.37% | 4.92% | 9.24% | 5.01% |
| D&A (Non-Cash Add-back) | 242M | 308M | 412M | 441M | 448M | 465M | 491M | 497M | 487M |
| EBIT | 1.7B | 1.9B | 2.04B | 2.25B | 2.72B | 2.89B | 3.19B | 3.38B | 3.58B |
| Net Interest Income | -175M | -181M | -205M | -237M | -230M | -187M | -153M | -136M | -150M |
| Interest Income | 0 | 31M | 37M | 12M | 6M | 50M | 105M | 106M | 93M |
| Interest Expense | 175M | 212M | 242M | 249M | 236M | 237M | 258M | 242M | 243M |
| Other Income/Expense | -202M | -191M | -217M | -273M | -315M | -272M | -133M | -259M | -237M |
| Pretax Income | 1.52B▲ 0% | 1.69B▲ 10.8% | 1.8B▲ 6.6% | 2B▲ 10.8% | 2.49B▲ 24.6% | 2.66B▲ 6.8% | 2.94B▲ 10.5% | 3.13B▲ 6.7% | 3.36B▲ 7.2% |
| Pretax Margin % | 28.74% | 29.01% | 28.77% | 29.9% | 32% | 32.87% | 34.36% | 33.85% | 35.49% |
| Income Tax | 663M | 266M | 301M | 360M | 454M | 545M | 596M | 637M | 687M |
| Effective Tax Rate % | 43.48% | 15.74% | 16.71% | 18.04% | 18.25% | 20.52% | 20.3% | 20.33% | 20.45% |
| Net Income | 864M▲ 0% | 1.43B▲ 65.3% | 1.5B▲ 5.0% | 1.64B▲ 9.2% | 2.04B▲ 24.4% | 2.11B▲ 3.8% | 2.34B▲ 10.9% | 2.49B▲ 6.1% | 2.67B▲ 7.5% |
| Net Margin % | 16.28% | 24.52% | 23.96% | 24.54% | 26.2% | 26.16% | 27.43% | 26.86% | 28.23% |
| Net Income Growth % | 5.24% | 65.28% | 5.04% | 9.2% | 24.36% | 3.78% | 10.88% | 6.06% | 7.52% |
| Net Income (Continuing) | 862M | 1.42B | 1.5B | 1.64B | 2.03B | 2.11B | 2.34B | 2.5B | 2.67B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 16M | 0 | 0 | 4M | 1M | -2M | -6M | 0 | 0 |
| EPS (Diluted) | 1.75▲ 0% | 2.93▲ 67.4% | 3.11▲ 6.1% | 3.42▲ 10.0% | 4.27▲ 24.9% | 4.49▲ 5.2% | 5.07▲ 12.9% | 5.47▲ 7.9% | 6.02▲ 10.1% |
| EPS Growth % | 6.06% | 67.43% | 6.14% | 9.97% | 24.85% | 5.15% | 12.92% | 7.89% | 10.05% |
| EPS (Basic) | 1.76 | 2.96 | 3.14 | 3.44 | 4.29 | 4.51 | 5.08 | 5.47 | 6.03 |
| Diluted Shares Outstanding | 493.16M | 486.9M | 481.79M | 478.57M | 476.72M | 470.38M | 462.27M | 454.85M | 443.83M |
| Basic Shares Outstanding | 489.92M | 483.06M | 478.13M | 475.5M | 474.35M | 468.89M | 461.17M | 454.2M | 443.44M |
| Dividend Payout Ratio | 23.84% | 17.02% | 20.93% | 23.2% | 23.27% | 28.9% | 29.52% | 31.62% | 33.26% |
ZTS Balance Sheet
Zoetis Inc. (ZTS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 4.22B | 4.4B | 4.75B | 6.61B | 6.93B | 7.51B | 6.34B | 5.99B | 6.77B |
| Cash & Short-Term Investments | 1.56B | 1.7B | 1.93B | 3.6B | 3.48B | 3.58B | 2.04B | 1.99B | 2.31B |
| Cash Only | 1.56B | 1.6B | 1.93B | 3.6B | 3.48B | 3.58B | 2.04B | 1.99B | 2.31B |
| Short-Term Investments | 0 | 99M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 998M | 1.04B | 1.09B | 1.01B | 1.13B | 1.22B | 1.3B | 1.32B | 1.59B |
| Days Sales Outstanding | 68.64 | 64.92 | 63.32 | 55.39 | 53.18 | 54.89 | 55.71 | 51.9 | 61.3 |
| Inventory | 1.43B | 1.39B | 1.41B | 1.63B | 1.92B | 2.35B | 2.56B | 2.31B | 2.43B |
| Days Inventory Outstanding | 279.43 | 250.35 | 239.71 | 268.03 | 284.86 | 328.7 | 345.34 | 294.3 | 317.45 |
| Other Current Assets | 228M | 276M | 320M | 368M | 392M | 369M | 436M | 379M | 436M |
| Total Non-Current Assets | 4.37B | 6.38B | 6.8B | 7B | 6.97B | 7.42B | 7.94B | 8.25B | 8.7B |
| Property, Plant & Equipment | 1.44B | 1.66B | 2.13B | 2.39B | 2.6B | 2.97B | 3.43B | 3.61B | 3.97B |
| Fixed Asset Turnover | 3.70x | 3.51x | 2.94x | 2.79x | 2.99x | 2.72x | 2.49x | 2.56x | 2.39x |
| Goodwill | 1.51B | 2.52B | 2.59B | 2.69B | 2.68B | 2.75B | 2.76B | 2.72B | 2.77B |
| Intangible Assets | 1.27B | 2.05B | 1.89B | 1.71B | 1.47B | 1.38B | 1.34B | 1.13B | 998M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 30M | 0 |
| Other Non-Current Assets | 75M | 94M | 98M | 106M | 111M | 147M | 206M | 220M | 328M |
| Total Assets | 8.59B▲ 0% | 10.78B▲ 25.5% | 11.54B▲ 7.1% | 13.61B▲ 17.9% | 13.9B▲ 2.1% | 14.93B▲ 7.4% | 14.29B▼ 4.3% | 14.24B▼ 0.3% | 15.47B▲ 8.6% |
| Asset Turnover | 0.62x | 0.54x | 0.54x | 0.49x | 0.56x | 0.54x | 0.60x | 0.65x | 0.61x |
| Asset Growth % | 12.25% | 25.52% | 7.13% | 17.88% | 2.14% | 7.37% | -4.28% | -0.34% | 8.64% |
| Total Current Liabilities | 1.09B | 1.22B | 1.81B | 2.17B | 1.8B | 3.17B | 1.89B | 3.41B | 2.23B |
| Accounts Payable | 261M | 313M | 301M | 457M | 436M | 405M | 411M | 433M | 487M |
| Days Payables Outstanding | 51.11 | 56.33 | 51.17 | 75.24 | 64.59 | 56.77 | 55.36 | 55.26 | 63.62 |
| Short-Term Debt | 0 | 9M | 500M | 604M | 0 | 1.35B | 3M | 1.35B | 53M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11M |
| Other Current Liabilities | 280M | 300M | 331M | 388M | 459M | 397M | 484M | 566M | 895M |
| Current Ratio | 3.85x | 3.60x | 2.63x | 3.05x | 3.86x | 2.37x | 3.36x | 1.75x | 3.03x |
| Quick Ratio | 2.55x | 2.46x | 1.85x | 2.30x | 2.79x | 1.63x | 2.00x | 1.08x | 1.94x |
| Cash Conversion Cycle | 296.96 | 258.94 | 251.86 | 248.18 | 273.46 | 326.81 | 345.69 | 290.93 | 315.13 |
| Total Non-Current Liabilities | 5.71B | 7.37B | 7.03B | 7.67B | 7.56B | 7.36B | 7.41B | 6.05B | 9.9B |
| Long-Term Debt | 4.95B | 6.44B | 5.95B | 6.59B | 6.59B | 6.55B | 6.56B | 5.22B | 9.24B |
| Capital Lease Obligations | 0 | 0 | 164M | 163M | 151M | 186M | 188M | 174M | 202M |
| Deferred Tax Liabilities | 380M | 474M | 434M | 378M | 320M | 142M | 146M | 167M | 139M |
| Other Non-Current Liabilities | 373M | 452M | 486M | 530M | 496M | 475M | 508M | 494M | 305M |
| Total Liabilities | 6.8B | 8.59B | 8.84B | 9.84B | 9.36B | 10.52B | 9.29B | 9.47B | 12.14B |
| Total Debt | 4.95B | 6.45B | 6.61B | 7.36B | 6.74B | 8.09B | 6.75B | 6.74B | 9.49B |
| Net Debt | 3.39B | 4.86B | 4.68B | 3.76B | 3.26B | 4.51B | 4.72B | 4.76B | 7.18B |
| Debt / Equity | 2.77x | 2.95x | 2.44x | 1.95x | 1.48x | 1.84x | 1.35x | 1.41x | 2.85x |
| Debt / EBITDA | 2.52x | 2.95x | 2.72x | 2.72x | 2.07x | 2.38x | 1.90x | 1.73x | 2.32x |
| Net Debt / EBITDA | 1.72x | 2.22x | 1.93x | 1.39x | 1.00x | 1.33x | 1.32x | 1.22x | 1.76x |
| Interest Coverage | 9.71x | 8.97x | 8.44x | 9.02x | 11.54x | 12.21x | 12.38x | 13.95x | 14.74x |
| Total Equity | 1.79B▲ 0% | 2.19B▲ 22.3% | 2.71B▲ 23.9% | 3.77B▲ 39.3% | 4.54B▲ 20.4% | 4.4B▼ 3.1% | 4.99B▲ 13.4% | 4.77B▼ 4.4% | 3.33B▼ 30.2% |
| Equity Growth % | 19.15% | 22.34% | 23.94% | 39.33% | 20.43% | -3.1% | 13.35% | -4.43% | -30.17% |
| Book Value per Share | 3.62 | 4.49 | 5.62 | 7.88 | 9.53 | 9.36 | 10.80 | 10.49 | 7.51 |
| Total Shareholders' Equity | 1.77B | 2.19B | 2.71B | 3.77B | 4.54B | 4.41B | 5B | 4.77B | 3.33B |
| Common Stock | 5M | 5M | 5M | 5M | 5M | 5M | 5M | 5M | 5M |
| Retained Earnings | 2.11B | 3.27B | 4.43B | 5.66B | 7.19B | 8.67B | 10.29B | 11.97B | 13.74B |
| Treasury Stock | -852M | -1.49B | -2.04B | -2.23B | -2.95B | -4.54B | -5.6B | -7.45B | -10.69B |
| Accumulated OCI | -505M | -629M | -726M | -730M | -764M | -817M | -839M | -940M | -834M |
| Minority Interest | 16M | 0 | 0 | 4M | 1M | -2M | -6M | 0 | 0 |
ZTS Cash Flow Statement
Zoetis Inc. (ZTS) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 1.35B | 1.79B | 1.79B | 2.13B | 2.21B | 1.91B | 2.35B | 2.95B | 2.9B |
| Operating CF Margin % | 25.36% | 30.73% | 28.67% | 31.85% | 28.46% | 23.66% | 27.54% | 31.9% | 30.68% |
| Operating CF Growth % | 88.78% | 32.99% | 0.28% | 18.44% | 4.09% | -13.6% | 23.06% | 25.5% | -1.66% |
| Net Income | 862M | 1.42B | 1.5B | 1.64B | 2.03B | 2.11B | 2.34B | 2.5B | 2.67B |
| Depreciation & Amortization | 242M | 308M | 412M | 441M | 448M | 465M | 491M | 497M | 487M |
| Stock-Based Compensation | 44M | 53M | 67M | 59M | 58M | 62M | 60M | 74M | 83M |
| Deferred Taxes | 127M | -112M | -79M | -62M | -80M | -286M | -61M | -338M | -52M |
| Other Non-Cash Items | 100M | 5M | 46M | 137M | 96M | 259M | 31M | 145M | 121M |
| Working Capital Changes | -29M | 112M | -151M | -85M | -343M | -699M | -512M | 79M | -408M |
| Change in Receivables | -50M | -67M | -69M | 74M | -155M | -137M | -102M | -61M | -236M |
| Change in Inventory | 19M | 61M | -104M | -346M | -366M | -486M | -361M | -40M | -199M |
| Change in Payables | -10M | 37M | -10M | 147M | -17M | -29M | 13M | 31M | 46M |
| Cash from Investing | -270M | -2.26B | -504M | -572M | -458M | -883M | -777M | -315M | -748M |
| Capital Expenditures | -224M | -338M | -460M | -453M | -477M | -586M | -732M | -655M | -621M |
| CapEx % of Revenue | 4.22% | 5.8% | 7.35% | 6.79% | 6.13% | 7.25% | 8.57% | 7.08% | 6.56% |
| Acquisitions | -82M | -2B | -195M | -113M | -14M | -312M | -59M | 285M | -24M |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 36M | -289M | -447M | -432M | 1M | 1M | 6M | 60M | -96M |
| Cash from Financing | -251M | 533M | -951M | 123M | -1.86B | -904M | -3.11B | -2.66B | -1.87B |
| Debt Issued (Net) | 481M | 1.5B | -9M | 744M | -604M | 1.35B | -1.35B | -3M | 2.27B |
| Equity Issued (Net) | -500M | -698M | -626M | -250M | -743M | -1.59B | -1.09B | -1.86B | -3.23B |
| Dividends Paid | -206M | -243M | -314M | -380M | -474M | -611M | -692M | -786M | -889M |
| Share Repurchases | -500M | -698M | -626M | -250M | -743M | -1.59B | -1.09B | -1.86B | -3.23B |
| Other Financing | -26M | -30M | -2M | 9M | -45M | -49M | 24M | -13M | -14M |
| Net Change in Cash | 837M▲ 0% | 38M▼ 95.5% | 332M▲ 773.7% | 1.67B▲ 403.0% | -119M▼ 107.1% | 96M▲ 180.7% | -1.54B▼ 1704.2% | -54M▲ 96.5% | 325M▲ 701.9% |
| Free Cash Flow | 1.12B▲ 0% | 1.45B▲ 29.4% | 1.33B▼ 8.1% | 1.67B▲ 25.3% | 1.74B▲ 3.8% | 1.33B▼ 23.6% | 1.62B▲ 22.2% | 2.3B▲ 41.8% | 2.28B▼ 0.7% |
| FCF Margin % | 21.14% | 24.93% | 21.33% | 25.06% | 22.33% | 16.41% | 18.97% | 24.83% | 24.12% |
| FCF Growth % | 125.75% | 29.41% | -8.06% | 25.32% | 3.77% | -23.62% | 22.25% | 41.76% | -0.65% |
| FCF per Share | 2.28 | 2.98 | 2.77 | 3.50 | 3.64 | 2.82 | 3.51 | 5.05 | 5.14 |
| FCF Conversion (FCF/Net Income) | 1.56x | 1.25x | 1.20x | 1.30x | 1.09x | 0.90x | 1.00x | 1.19x | 1.09x |
| Interest Paid | 167M | 190M | 247M | 257M | 253M | 242M | 295M | 274M | 261M |
| Taxes Paid | 455M | 336M | 418M | 418M | 548M | 638M | 754M | 892M | 715M |
ZTS Key Ratios
Zoetis Inc. (ZTS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 63.4% | 52.6% | 71.92% | 61.31% | 50.55% | 48.98% | 47.26% | 49.9% | 50.94% | 65.99% |
| Return on Invested Capital (ROIC) | 20.97% | 24.87% | 23.1% | 20.98% | 22.81% | 27.41% | 26.27% | 24.72% | 26.45% | 26.92% |
| Gross Margin | 64.3% | 64.88% | 65.18% | 65.7% | 66.79% | 68.31% | 67.77% | 68.28% | 69.1% | 70.49% |
| Net Margin | 16.8% | 16.28% | 24.52% | 23.96% | 24.54% | 26.2% | 26.16% | 27.43% | 26.86% | 28.23% |
| Debt / Equity | 2.98x | 2.77x | 2.95x | 2.44x | 1.95x | 1.48x | 1.84x | 1.35x | 1.41x | 2.85x |
| Interest Coverage | 8.40x | 9.71x | 8.97x | 8.44x | 9.02x | 11.54x | 12.21x | 12.38x | 13.95x | 14.74x |
| FCF Conversion | 0.87x | 1.56x | 1.25x | 1.20x | 1.30x | 1.09x | 0.90x | 1.00x | 1.19x | 1.09x |
| Revenue Growth | 2.58% | 8.57% | 9.76% | 7.47% | 6.63% | 16.49% | 3.91% | 5.74% | 8.33% | 2.28% |
ZTS SEC Filings & Documents
Zoetis Inc. (ZTS) SEC filings — annual & quarterly reports (10-K, 10-Q)
ZTS Frequently Asked Questions
Zoetis Inc. (ZTS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Zoetis Inc. (ZTS) reported $9.47B in revenue for fiscal year 2025. This represents a 164% increase from $3.58B in 2010.
Zoetis Inc. (ZTS) grew revenue by 2.3% over the past year. Growth has been modest.
Yes, Zoetis Inc. (ZTS) is profitable, generating $2.67B in net income for fiscal year 2025 (28.2% net margin).
Dividend & Returns
Yes, Zoetis Inc. (ZTS) pays a dividend with a yield of 1.80%. This makes it attractive for income-focused investors.
Zoetis Inc. (ZTS) has a return on equity (ROE) of 66.0%. This is excellent, indicating efficient use of shareholder capital.
Zoetis Inc. (ZTS) generated $2.28B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More ZTS
Zoetis Inc. (ZTS) financial analysis — history, returns, DCA and operating performance tools
Full ZTS Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates